RN Mobile Menu

Search form




Lupus (©Designer491/Shutterstock.com)

New research shows even more potential for targeted therapies in systemic lupus erythematosus, a disease that is often characterized as a combination several systemic autoimmune diseases.

Researchers reporting at the American Society of Hematology annual meeting this week say there is a link between a treatment for autoimmune disease and the development of leukemia.

Doctor and patients perceive the importance of lupus medications differently. In this article, we feature a UAB-derived decision aid that highlights key considerations.

Less than half of patients with systemic lupus erythematosus reach low disease activity. Why? Experts say focus on disease duration, phenotype and other accepted predictive factors.

Diagnosed with systemic lupus erythematosus and chikungunya, a woman embarks on a cross-continent trip for treatment and diagnosis at a city hospital.

Patients with systemic lupus erythematosus have a 38 percent higher adjusted risk of stroke, shows a Harvard study presented at ACR 2016.

A report in Joint Bone Spine conveys which biotherapies offer the most potential for systemic lupus erythematosus.


Subscribe to Lupus on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.